Trial Profile
NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Dec 2024
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImmunityBio; NantKwest
Most Recent Events
- 11 Dec 2024 Status changed from active, no longer recruiting to discontinued. ( low enrollment )
- 28 Mar 2022 Planned End Date changed from 30 Dec 2021 to 30 Dec 2022.
- 28 Mar 2022 Planned primary completion date changed from 30 Dec 2021 to 30 Dec 2022.